Showing results (11-20 of 290) with videos related to
Sort By:
Pageof 29
BMC Medicine|February 14, 2016
Drug safety: withdrawn medications are only part of the pictureNigel S B RawsonFrontiers in Public Health|November 16, 2020
Leading Causes of Mortality and Prescription Drug Coverage in Canada and New ZealandNigel S B RawsonRegulatory Toxicology and Pharmacology : RTP|August 12, 2015
Health Canada's use of priority review status for drugs for unmet needsNigel S B RawsonClinical Therapeutics|June 18, 2003
Timeliness of review and approval of new drugs in Canada from 1999 through 2001: is progress being made?Nigel S B RawsonJournal of Population Therapeutics and Clinical Pharmacology = Journal De La Therapeutique Des Populations Et De La Pharmacologie Clinique|June 17, 2020
Regulatory approval and public drug plan listing of new drugs for rare disorders in Canada and New ZealandNigel S B RawsonPharmacoepidemiology and Drug Safety|August 4, 2009
Access to linked administrative healthcare utilization data for pharmacoepidemiology and pharmacoeconomics research in Canada: anti-viral drugs as an exampleNigel S B RawsonClinicoeconomics and Outcomes Research : CEOR|December 29, 2025
Consequences of Canada's Drug Agency Reimbursement Recommendations for New Medicines and Pan-Canadian Pharmaceutical Alliance Price Negotiations on Patient AccessNigel S B RawsonOrphanet Journal of Rare Diseases|June 13, 2022
Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits?Nigel S B RawsonJournal of Population Therapeutics and Clinical Pharmacology = Journal De La Therapeutique Des Populations Et De La Pharmacologie Clinique|May 12, 2012
Commentary: Canadian Association for Population Therapeutics: the past, present and future - a personal viewpoint and a call to actionNigel S B RawsonRegulatory Toxicology and Pharmacology : RTP|May 7, 2018
Canadian, European and United States new drug approval times now relatively similarNigel S B RawsonPageof 29